QuantRx Reports Positive Phase I Results of Myocardial Imaging Tracer
Posted on: Thursday, 24 July 2008, 12:01 CDT
QuantRx Biomedical has announced that the company's FluoroPharma has achieved positive Phase I results for BFPET, its novel Fluorine-18 labeled tracer for myocardial perfusion imaging.
The Phase I trial was designed to evaluate safety, distribution and dosimetry of BFPET in 12 healthy subjects following a single dose injection at rest.
BFPET is FluoroPharma's second cardiovascular product to complete Phase I clinical development. BFPET is a positron emission tomography (PET) imaging agent, designed to assess the blood flow in the heart (myocardial perfusion).
Fischman, professor of Radiology at Harvard Medical School, said: "BFPET Phase I data demonstrates that the agent has a favorable dosimetry and pharmacokinetics profile and is well tolerated. All safety endpoints were achieved with no adverse events and no clinically significant changes noted in follow-up clinical and laboratory testing. Biodistribution results indicate fast blood clearance, rapid and stable myocardial uptake and high heart to background ratios."
David Elmaleh, FluoroPharma's founder and chief scientific advisor, said: "The high quality cardiac images obtained in this study indicate that new cardiac PET imaging agents can expand the applications of PET beyond the use of FDG in oncology and neurology. With two cardiac agents in clinical development and a third in our pipeline, FluoroPharma hopes to pave the way for cardiovascular PET."
Source: Datamonitor
Related Articles
- FluoroPharma Reports Positive Results of Cardiac Imaging Tracer
- Merck Initiates Phase II/III Clinical Trial of SLE
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- MedSolutions Launches Outcomes-Focused Cardiac Imaging(TM): Industry's Most Rigorous Cardiac Imaging Management Product
- ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine
- Advanced Cardiac Imaging Cardiologist Farzan Rajput, M.D., Joins Pacific Coast Cardiology and Pacific Coast Imaging
- Nutra Pharma Announces Final Approval to Begin Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
- Noninvasive Diagnosis of Coronary Artery Disease in Patients With Diabetes By Dobutamine Stress Real-Time Myocardial Contrast Perfusion Imaging
- Dendreon Completes Enrollment in Phase 3 PROTECT (P-11) Clinical Trial of Provenge in Early Stage Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds